Prostate Cancer: A Review of Genetics, Current Biomarkers and Personalised Treatments
Cancer Reports · 2024-10 · 7 (10)
DOI: 10.1002/cnr2.70016 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer Reports, online erschienen am 16.10.2024. Verfasst von Trevor K Wilson und 1 weiteren Autor:innen. Beteiligte Einrichtung: Discipline of Genetics, School of Life Sciences, College of Agriculture, Engineering, and Science, University of KwaZulu-Natal, Durban, South Africa. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Precision Medicine, Biomarkers, Tumor. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 270 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Prostate cancer is the second leading cause of cancer deaths in men, second only to lung cancer. Despite this, diagnosis and prognosis methods remain limited, with effective treatments being few and far between. Traditionally, prostate cancer is initially tested for through a prostate serum antigen (PSA) test and a digital rectum examination (DRE), followed by confirmation through an invasive prostate biopsy. The DRE and biopsy are uncomfortable for the patient, so less invasive, accurate diagnostic tools are needed. Current diagnostic tools, along with genes that hold possible biomarker uses in diagnosis, prognosis and indications for personalised treatment plans, were reviewed in this article. Recent Findings Several genes from multiple families have been identified as possible biomarkers for disease, including those from the MYC and ETS families, as well as several tumour suppressor genes, Androgen Receptor signalling genes and DNA repair genes. There have also been advances in diagnostic tools, including MRI‐targeted and liquid biopsies. Several personalised treatments have been developed over the years, including those that target metabolism‐driven prostate cancer or those that target inflammation‐driven cancer.
Conclusion
Several advances have been made in prostate cancer diagnosis and treatment, but the disease still grows year by year, leading to more and more deaths annually. This calls for even more research into this disease, allowing for better diagnosis and treatment methods and a better chance of patient survival.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Discipline of Genetics, School of Life Sciences, College of Agriculture, Engineering, and Science, University of KwaZulu-Natal, Durban, South Africa.
ORCID-Profile: Trevor K Wilson, Oliver T Zishiri
Zitieren
APA
Wilson, T. K., & Zishiri, O. T. (2024). Prostate Cancer: A Review of Genetics, Current Biomarkers and Personalised Treatments. Cancer Reports, 7(10). https://doi.org/10.1002/cnr2.70016
Vancouver
Wilson TK, Zishiri OT. Prostate Cancer: A Review of Genetics, Current Biomarkers and Personalised Treatments. Cancer Reports. 2024;7(10). doi:10.1002/cnr2.70016
BibTeX
@article{Wilson2024,
author = {Wilson, Trevor K and Zishiri, Oliver T},
title = {Prostate Cancer: A Review of Genetics, Current Biomarkers and Personalised Treatments},
journal = {Cancer Reports},
year = {2024},
volume = {7},
number = {10},
doi = {10.1002/cnr2.70016}
}
EUVIMED